Chengdu Easton Biopharmaceuticals Co Ltd Total Liabilities
Chengdu Easton Biopharmaceuticals Co Ltd total liabilities. Based on the latest financial reports, Chengdu Easton Biopharmaceuticals Co Ltd (688513) has total liabilities worth CN¥802.42 Million CNY (≈ $117.42 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check 688513 asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Chengdu Easton Biopharmaceuticals Co Ltd (2013–2025)
Total liabilities of Chengdu Easton Biopharmaceuticals Co Ltd from 2013 to 2025. This chart illustrates how Chengdu Easton Biopharmaceuticals Co Ltd's total liabilities have evolved over time, based on quarterly financial data.
Chengdu Easton Biopharmaceuticals Co Ltd Competitors by Total Liabilities
The table below lists competitors of Chengdu Easton Biopharmaceuticals Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
MAC Copper Ltd
AU:MAC
|
Australia | AU$870.02 Million |
|
Virtus Investment Partners, Inc.
NASDAQ:VRTS
|
USA | $2.88 Billion |
|
Lindsay Corporation
NYSE:LNN
|
USA | $322.55 Million |
|
Suzhou Douson Drilling & Production Equipment Co Ltd
SHG:603800
|
China | CN¥1.56 Billion |
|
Beijing Urban Rural Commercial Group Co Ltd
SHG:600861
|
China | CN¥7.88 Billion |
|
Zimplats Holdings Ltd
AU:ZIM
|
Australia | AU$813.69 Million |
|
HYDROGRAPH CLEAN POWER
F:M98
|
Germany | €2.34 Million |
|
Zoomlion Heavy Industry Science and Technology Co. Ltd
F:8CZ
|
Germany | €84.70 Billion |
Liability Composition Analysis (2013–2025)
This chart breaks down Chengdu Easton Biopharmaceuticals Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Chengdu Easton Biopharmaceuticals Co Ltd (688513) total assets.
Liquidity & Leverage Metrics
Chengdu Easton Biopharmaceuticals Co Ltd Total Liabilities Ratios Explained
Chengdu Easton Biopharmaceuticals Co Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.25 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.27 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.21 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Chengdu Easton Biopharmaceuticals Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Chengdu Easton Biopharmaceuticals Co Ltd (2013–2025)
The table below shows the annual total liabilities of Chengdu Easton Biopharmaceuticals Co Ltd from 2013 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥-2.87 Billion ≈ $-419.38 Million |
-508.14% |
| 2024-12-31 | CN¥702.21 Million ≈ $102.75 Million |
-5.53% |
| 2023-12-31 | CN¥743.33 Million ≈ $108.77 Million |
+29.71% |
| 2022-12-31 | CN¥573.08 Million ≈ $83.86 Million |
+18.50% |
| 2021-12-31 | CN¥483.60 Million ≈ $70.77 Million |
+11.02% |
| 2020-12-31 | CN¥435.61 Million ≈ $63.74 Million |
+50.40% |
| 2019-12-31 | CN¥289.64 Million ≈ $42.38 Million |
+39.58% |
| 2018-12-31 | CN¥207.50 Million ≈ $30.36 Million |
+41.45% |
| 2017-12-31 | CN¥146.70 Million ≈ $21.47 Million |
+12.48% |
| 2016-12-31 | CN¥130.43 Million ≈ $19.09 Million |
+200.42% |
| 2015-12-31 | CN¥43.42 Million ≈ $6.35 Million |
-45.63% |
| 2014-12-31 | CN¥79.85 Million ≈ $11.68 Million |
-7.42% |
| 2013-12-31 | CN¥86.24 Million ≈ $12.62 Million |
-- |
About Chengdu Easton Biopharmaceuticals Co Ltd
Chengdu Easton Biopharmaceuticals Co., Ltd., together with its subsidiaries, engages in the research, development, manufacturing, and commercialization of pharmaceutical products in China and internationally. The company offers active pharmaceutical ingredients; finished dosage forms, including capsules, tablets, and injections; pharmaceutical intermediates; biological drugs; and generic drugs. I… Read more